heme has been researched along with hmr 1766 in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Busch, AE; Jannek, C; Linz, W; Löhn, M; Martorana, PA; Mülsch, A; Pistorius, A; Rütten, H; Schindler, PW; Schindler, U; Schönafinger, K; Sohn, M; Strobel, H; Töpfer, A | 1 |
| Amann, K; Benz, K; Linz, W; Orth, SR; Rütten, H; Schindler, U; Simonaviciene, A | 1 |
| Dalkas, G; Kotanidou, A; Papapetropoulos, A; Pyriochou, A; Roussos, C; Spyroulias, G; van Eickels, M; Zhou, Z | 1 |
| Schmidt, HH; Schmidt, PM; Stasch, JP | 1 |
| Hoffmann, LS; Keim, Y; Schaefer, S; Schmidt, HH; Schmidt, PM; Stasch, JP | 1 |
1 review(s) available for heme and hmr 1766
| Article | Year |
|---|---|
NO- and haem-independent soluble guanylate cyclase activators.
Topics: Animals; Benzoates; Cardiovascular Diseases; Clinical Trials as Topic; Drug Delivery Systems; Enzyme Activators; Guanylate Cyclase; Heme; Humans; Nitric Oxide; ortho-Aminobenzoates; Oxidative Stress; Receptors, Cytoplasmic and Nuclear; Risk Factors; Soluble Guanylyl Cyclase; Sulfonamides | 2009 |
4 other study(ies) available for heme and hmr 1766
| Article | Year |
|---|---|
Biochemistry and pharmacology of novel anthranilic acid derivatives activating heme-oxidized soluble guanylyl cyclase.
Topics: Animals; Blood Pressure; Cattle; Cyclic GMP-Dependent Protein Kinases; Enzyme Activation; Guanylate Cyclase; Heme; ortho-Aminobenzoates; Oxidation-Reduction; Sulfonamides; Vasodilator Agents | 2006 |
Blood pressure-independent effect of long-term treatment with the soluble heme-independent guanylyl cyclase activator HMR1766 on progression in a model of noninflammatory chronic renal damage.
Topics: Animals; Blood Pressure; Disease Models, Animal; Disease Progression; Guanylate Cyclase; Heme; Kidney Failure, Chronic; Male; ortho-Aminobenzoates; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Soluble Guanylyl Cyclase; Sulfonamides; Time | 2007 |
Soluble guanylyl cyclase activation by HMR-1766 (ataciguat) in cells exposed to oxidative stress.
Topics: Animals; Chlorocebus aethiops; COS Cells; Cyclic GMP; Dose-Response Relationship, Drug; Drug Tolerance; Enzyme Activation; Enzyme Activators; Guanylate Cyclase; Heme; Male; Models, Molecular; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Nitric Oxide Donors; ortho-Aminobenzoates; Oxidants; Oxidative Stress; Protein Conformation; Protein Structure, Tertiary; Rats; Rats, Wistar; Reactive Oxygen Species; Receptors, Cytoplasmic and Nuclear; Soluble Guanylyl Cyclase; Sulfonamides; Transfection; Vasodilator Agents | 2008 |
Distinct molecular requirements for activation or stabilization of soluble guanylyl cyclase upon haem oxidation-induced degradation.
Topics: Aequorin; Animals; Benzoates; Binding Sites; Binding, Competitive; CHO Cells; Cricetinae; Cricetulus; Cyclic AMP; Cyclic Nucleotide-Gated Cation Channels; Dose-Response Relationship, Drug; Endothelial Cells; Enzyme Activation; Enzyme Activators; Enzyme Inhibitors; Enzyme Stability; Genes, Reporter; Guanylate Cyclase; Heme; Molecular Structure; Mutation; ortho-Aminobenzoates; Oxadiazoles; Oxidation-Reduction; Protoporphyrins; Pyrazoles; Pyridines; Quinoxalines; Rats; Receptors, Cytoplasmic and Nuclear; Soluble Guanylyl Cyclase; Structure-Activity Relationship; Sulfonamides; Swine; Transfection | 2009 |